

Supplementary Table 3. Baseline clinical and biochemical characteristic of study subjects based on baseline serum uric acid quartile categories and both sexes according to incident metabolic syndrome: female

Characteristic	Percent changes in serum uric acid (not incident MetS in female, n = 4,462)				Percent changes in serum uric acid (incident MetS in female, n = 901)					
	Quartile 1 (≤-5.6%, n=1,048)	Quartile 2 (-5.5% to 4.1%, n=1,069)	Quartile 3 (4.2% to 14.6%, n=1,164)	Quartile 4 (≥14.7%, n=1,181)	P value	Quartile 1 (≤-5.6%, n=298)	Quartile 2 (-5.5% to 4.1%, n=255)	Quartile 3 (4.2% to 14.6%, n=184)	Quartile 4 (≥14.7%, n=164)	P value
Age, yr	49.2±8.2	48.9±7.3	48.5±7.0	47.9±6.2	0.000	53.4±8.0	51.7±7.2	52.8±7.7	51.3±6.4	0.014
Smoking status	0.886									
Current smoker	19 (1.8)	20 (1.9)	20 (1.7)	25 (2.1)		3 (1.0)	2 (0.8)	4 (2.2)	2 (1.2)	
Ex-smoker	39 (3.7)	29 (2.7)	36 (3.1)	37 (3.1)		8 (2.7)	8 (3.1)	2 (1.1)	3 (1.8)	
Non-smoker	990 (94.5)	1,020 (95.4)	1,108 (95.2)	1,119 (94.8)		287 (96.3)	245 (96.1)	178 (96.7)	159 (97.0)	
BMI, kg/m ²	21.9±2.4	21.7±2.3	21.7±2.3	21.7±2.1	0.115	24.1±2.7	23.8±2.5	23.4±2.2	23.7±2.6	0.006
Waist circumference, cm	73.9±6.6	73.5±6.2	73.3±6.0	73.4±5.8	0.031	80.0±7.1	79.0±6.2	78.1±5.9	78.5±6.5	0.003
Fat-free mass, %	72.4±5.4	72.7±5.4	72.9±5.2	72.7±5.2	0.137	68.8±5.2	69.2±5.0	70.1±4.7	69.6±5.2	0.018
Systolic BP, mm Hg	107.1±15.0	107.3±14.4	107.4±14.0	108.1±14.0	0.092	114.7±15.2	115.1±15.3	115.3±15.0	116.2±15.1	0.355
Diastolic BP, mm Hg	65.2±10.2	64.9±9.7	64.6±9.9	65.5±9.8	0.612	68.4±9.6	68.8±10.1	68.7±9.7	71.1±10.0	0.014
eGFR, mL/min/1.73 m ²	88.2±12.3	90.3±12.5	91.2±11.9	93.4±12.7	0.000	87.6±12.6	90.2±13.9	91.9±12.1	89.6±12.2	0.017
Fasting glucose, mg/dL	85.2±10.0	85.0±8.2	84.7±8.6	85.1±8.9	0.741	89.4±13.0	88.7±8.7	89.3±14.3	90.9±16.0	0.271
Fasting insulin, μU/mL ^a	7.5 (5.9-9.4)	7.8 (5.8-9.5)	7.8 (6.1-10.0)	7.8 (6.3-10.1)	0.131	8.9 (7.0-11.7)	9.1 (7.4-10.9)	8.4 (7.0-10.7)	9.0 (7.0-11.5)	0.540
HOMA-IR ^a	1.6 (1.2-2.0)	1.6 (1.2-2.1)	1.6 (1.3-2.1)	1.7 (1.3-2.2)	0.182	2.0 (1.5-2.6)	2.0 (1.6-2.4)	1.9 (1.5-2.4)	2.0 (1.4-2.6)	0.826
Total cholesterol, mg/dL	192.9±34.2	192.3±31.0	190.1±32.5	187.0±31.6	0.000	199.0±34.6	197.9±36.1	199.2±32.2	195.4±37.8	0.421
TG, mg/dL	79.0 (61.0-102.5)	81.0 (64.0-102.0)	80.0 (61.0-105.0)	78.0 (61.0-103.0)	0.352	109.5 (82.0-140.0)	106.0 (86.5-141.0)	115.0 (89.0-143.0)	106.0 (83.5-137.0)	0.560
LDL-C, mg/dL	120.9±29.9	119.9±27.8	117.2±28.1	114.4±27.0	0.000	132.3±31.2	131.9±32.0	131.6±28.8	129.3±32.3	0.370
HDL-C, mg/dL	66.3±13.3	66.5±14.0	66.9±13.6	66.0±13.5	0.709	58.9±11.8	57.8±11.8	58.5±11.4	56.8±13.0	0.132
hs-CRP, mg/L	0.1±0.5	0.1±0.2	0.1±0.1	0.1±0.2	0.178	0.1±0.2	0.1±0.2	0.1±0.2	0.1±0.5	0.558
Baseline SUA, mg/dL	4.4±0.9	4.2±0.8	4.0±0.7	3.6±0.7	0.000	4.7±0.9	4.5±0.8	4.2±0.8	3.9±0.8	0.000
Change in SUA, %	-14.0±7.1	-0.7±2.7	9.0±3.0	27.9±13.0	0.000	-13.8±6.6	-0.5±2.6	8.9±3.1	25.9±11.1	0.000

Values are presented as mean ± standard deviation, number (%), or median (interquartile range). Characteristics of the study population according to the serum uric acid quartile were compared using one-way analysis of variance (ANOVA) or Kruskal-Wallis test for continuous variables and chi-square test for categorical variables. MetS, metabolic syndrome; BMI, body mass index; BP, blood pressure; eGFR, estimated glomerular filtration rate; HOMA-IR, homeostasis model assessment index for insulin resistance; TG, triglyceride; LDL-C, low density lipoprotein cholesterol; HDL-C, high density lipoprotein cholesterol; hs-CRP, high-sensitivity C-reactive protein; SUA, serum uric acid. ^an=2,792 female.